PulseAGGREGATOR

Gathering headlines…

Pulse Aggregator

Your news command center for 10,000+ sources. Search, filter, and set alerts — then cut through the noise with bias analysis, story clustering, and blindspot detection.

Legal

[Articles] Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study | Pulse Aggregator

← Back to feed

The Lancet Oncology#health

[Articles] Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 studytranslating…

just nowFactuality: 72/100UnknownLancet Publishing

STRIDE plus lenvatinib plus TACE showed a statistically significant progression-free survival improvement versus TACE. These findings support a STRIDE-based regimen as a potential new treatment option for people with embolisation-eligible HCC; additional follow-up is being…

Read Original ↗